MC 1 50
Alternative Names: CD19 CAR-T cell therapy - Chongqing Precision Biotech; MC-1-50Latest Information Update: 26 Dec 2023
At a glance
- Originator Chongqing Precision Biotech Co., Ltd
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Leukaemia; Lymphoma
- Phase I B-cell lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 22 Dec 2023 Phase-I clinical trials in B-cell lymphoma (In adults, In the elderly, Second-line therapy or greater) in China (IV) (NCT06180174)
- 22 Dec 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (In adults, In the elderly, Second-line therapy or greater) in China (IV) (NCT06180174)
- 06 Jun 2023 Efficacy, adverse event, and pharmacokinetics data from a phase I/II trial in Leukaemia and Lymphoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)